Boehringer Ingelheim’s Strategic Move in Pet Health
Boehringer Ingelheim acquires Saiba Animal Health, boosting pet R&D with innovative therapeutic vaccines.
- Latest
- Trending
Boehringer Ingelheim acquires Saiba Animal Health, boosting pet R&D with innovative therapeutic vaccines.
PDS Biotech aligns with FDA for Phase 3 trial, reports Q2 2024 financials with reduced net loss and expenses.
Discover how Novo Nordisk, Moderna, and Regeneron are poised for growth amidst market volatility with innovative biotech solutions.
Bharat Biotech admits patent oversight on Covaxin, pledges to include ICMR scientists in new filings to uphold transparency and legal ...
Iovance Biotherapeutics has the potential to become a multiproduct company, and even if its stock doesn't soar quickly, it's still ...
Researchers have successfully developed a single-dose vaccine that prompts the production of T-cells and "memory" B cells to fight against ...
BioVaxys Technology Corp. finalizes agreement to acquire IMV Inc.'s immunotherapy technology portfolio, expanding its cancer vaccine portfolio and positioning itself ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.